- Home
- ENTA vs CHRS Comparison
ENTA vs CHRS Comparison
Compare ENTA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- CHRS
- Stock Information
- Founded
- ENTA 1995
- CHRS 2010
- Country
- ENTA United States
- CHRS United States
- Employees
- ENTA N/A
- CHRS N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENTA Health Care
- CHRS Health Care
- Exchange
- ENTA Nasdaq
- CHRS Nasdaq
- Market Cap
- ENTA 164.6M
- CHRS 194.1M
- IPO Year
- ENTA 2013
- CHRS 2014
- Fundamental
- Price
- ENTA $10.85
- CHRS $1.73
- Analyst Decision
- ENTA Strong Buy
- CHRS Strong Buy
- Analyst Count
- ENTA 5
- CHRS 4
- Target Price
- ENTA $21.00
- CHRS $4.51
- AVG Volume (30 Days)
- ENTA 554.0K
- CHRS 1.0M
- Earning Date
- ENTA 11-24-2025
- CHRS 11-07-2025
- Dividend Yield
- ENTA N/A
- CHRS N/A
- EPS Growth
- ENTA N/A
- CHRS N/A
- EPS
- ENTA N/A
- CHRS 1.55
- Revenue
- ENTA $64,806,000.00
- CHRS $272,209,000.00
- Revenue This Year
- ENTA $0.07
- CHRS N/A
- Revenue Next Year
- ENTA N/A
- CHRS $109.48
- P/E Ratio
- ENTA N/A
- CHRS $3.38
- Revenue Growth
- ENTA N/A
- CHRS 52.33
- 52 Week Low
- ENTA $4.09
- CHRS $0.66
- 52 Week High
- ENTA $15.34
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- ENTA 51.27
- CHRS 55.48
- Support Level
- ENTA $10.30
- CHRS $1.64
- Resistance Level
- ENTA $11.15
- CHRS $1.81
- Average True Range (ATR)
- ENTA 0.56
- CHRS 0.10
- MACD
- ENTA -0.17
- CHRS -0.02
- Stochastic Oscillator
- ENTA 19.19
- CHRS 48.10
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.